欧洲粘液补充市场 – 行业趋势和 2031 年预测

欧洲粘液补充市场分析与洞察

在粘弹性补充剂市场，产品配方和给药方法的进步提高了疗效和患者治疗效果。这些创新通过提供更好的疼痛缓解、延长关节功能和增加骨关节炎治疗选择，使患者和医疗保健提供者都受益。总体而言，粘弹性补充剂的发展有助于改善患有关节相关疾病的人的生活质量。                                

2023 年欧洲粘液补充剂市场规模为 4.7907 亿美元，预计到 2031 年将达到 8.8672 亿美元，预测期内（2024 年至 2031 年）的复合年增长率为 8.00%。这表明市场价值。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

市场定义

Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan for therapeutic purposes, the rheological properties (viscosity and elasticity) are low, and therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions and has comparable rheological properties to those of the fluid found in young, healthy individuals.

Europe Viscosupplementation Market Dynamics

Drivers

• Increasing Preference for Non-Surgical Treatments

With a growing emphasis on minimally invasive procedures and avoiding surgery whenever possible, viscosupplementation offers a viable alternative to invasive joint surgeries for osteoarthritis management, boosting its adoption.  For instance, in the United States, where over 30 million adults are affected by osteoarthritis, there's a growing inclination towards non-surgical options. Viscosupplementation injections provide symptomatic relief and improve joint function without the risks and recovery time associated with surgery, fostering its widespread adoption.

• Advancement in Technology

Ongoing advancements in medical technology are leading to the development of more advanced viscosupplements with improved efficacy and longer-lasting effects. These innovations attract both patients and healthcare providers, contributing to market growth. For instance, the development of cross-linked hyaluronic acid formulations has led to longer-lasting effects compared to traditional viscosupplements. These innovations not only attract patients seeking more effective pain relief and improved joint function but also garner the interest of healthcare providers, driving the expansion of the viscosupplementation market.

Opportunities

• Patient Preference for Pain Management

Patients are increasingly seeking non-opioid options for managing osteoarthritis pain to enhance their quality of life. Viscosupplementation stands out as a preferred choice due to its ability to alleviate joint pain without the risks associated with opioids. For instance, a recent study published in the Journal of Arthroplasty demonstrated that viscosupplementation for knee are effective in reducing pain scores for osteoarthritis patients, highlighting its appeal as a safe and effective pain management solution.

• Increasing Prevalence of Osteoarthritis

The global prevalence of osteoarthritis is escalating, driven by sedentary lifestyles, rising obesity rates, and sports-related injuries. This surge in affected individuals creates a substantial demand for viscosupplementation treatments. For instance, in the U.S. alone, osteoarthritis affects over 32.5 million adults, a figure expected to climb due to these contributing factors. Consequently, the market for viscosupplementation therapies is propelled by the expanding pool of patients seeking relief from joint pain and stiffness.

Restraints/Challenges

• Rising Competition from Alternative Therapies

Alternative therapies such as oral pain medications, physical therapy, and surgery pose significant competition to viscosupplementation. They are often perceived as more cost-effective and reliable options by patients and healthcare providers. This perception hampers the adoption of viscosupplementation, particularly in cases where alternatives offer similar or better outcomes. 

• High Cost of Treatment

Viscosupplementation injection cost are high which obstruct treatments, especially for uninsured patients, severely restrict accessibility and adoption rates. This financial barrier hampers market growth, as many individuals cannot afford the expensive procedures, thereby limiting the potential reach and impact of viscosupplementation in addressing joint-related conditions. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2022, Fidia Farmaceutici S.p.A. introduced its innovative Aesthetic Care portfolio featuring ACP technology at the 20th AMWC in Monte Carlo, showcasing its Hyal System and Hy-Tissue in Spain, highlighting hyaluronic acid research
• In December 2021, Avanos Medical acquired OrthogenRx, Inc., bolstering its viscosupplementation therapies with FDA-approved GenVisc850 and TriVisc for knee osteoarthritis treatment
• In August 2021, SEIKAGAKU CORPORATION launched HyLink in Taiwan, an intra-articular single-injection for viscosupplementation knee osteoarthritis, expanding its portfolio through TCM Biotech International Corp. HyLink, containing a cross-linked hyaluronate hydrogel, demonstrates Seikagaku's advanced cross-linking technology application

Europe Viscosupplementation Market Scope

The market is segmented on the basis of source, age group, molecular weight, injection, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

• Non-Animal Origin
• Animal Origin

 Molecular Weight

• Intermediate Molecular Weight
• Low Molecular Weight
• High Molecular Weight

 Injection

• Single Injection
• Three Injection
• Five Injection

 Age Group

• Geriatric
• Adult

 End User

• Hospitals
• Orthopedic Clinics
• Ambulatory Care Center
• Others

 Distribution Channel

• Direct Tender
• Retail Sales

Europe Viscosupplementation Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, source, age group, molecular weight, injection, end user, and distribution channel as referenced above.

The countries covered in the market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and Rest of Europe in Europe.

Germany is expected to dominate the viscosupplementation market, driven by a preference for shorter treatment regimens. Despite high prices, the rising prevalence of diseases such as osteoarthritis and increasing government approvals for three-injection viscosupplements are projected to fuel segment growth positively.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Europe Viscosupplementation Market Share Analysis

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• Anika Therapeutics, Inc.（美国）
• 生化学株式会社（日本）
• Bioventus（美国）
• Fidia Farmaceutici SpA（意大利）
• Ferring BV（荷兰）
• 赛诺菲安万特美国有限责任公司 (法国)
• Zimmer Biomet（美国）
• APTISSEN（美国）
• 强生服务公司（美国）
• LG化学（韩国）
• Viatris Inc.（美国）
• IBSA Institut Biochimique SA（瑞士）
• TRB CHEMEDICA SA（瑞士）
• Teva Pharmaceutical Industries Ltd.（以色列）

SKU-68855